ZION, IL--(Marketwired - September 30, 2016) - Cancer Treatment Centers of America® (CTCA) at Midwestern Regional Medical Center (Midwestern) in suburban Chicago has begun a new phase II clinical trial using a chemotherapy-free approach for early-stage, non-metastatic triple positive (hormone receptor positive or HR+ and HER2 positive) breast cancer.
The NEOADAPT clinical trial combines two HER2 targeted therapies, trastuzumab and pertuzumab, which are both FDA-approved neoadjuvant therapies (neoadjuvant means treatment given before surgery to shrink the cancer) normally given with chemotherapy, and an anti-hormonal treatment called aromatase inhibitors to target the hormone receptors. In this study, the use of trastuzumab and pertuzumab without the use of chemotherapy is investigational. The primary purpose of the study is to validate more treatment options that have less long-term toxicity for patients with triple-positive breast cancer.
Breast cancer is the most common cancer in women in the United States. Triple-positive breast cancer is a uniquely aggressive form of cancer. Data has shown that it typically does not respond as well to chemotherapy1,2, and may not respond to anti-hormonal treatments either. To date, despite representing about 10 percent of all breast cancers, very few studies have been completed that have evaluated treatments tailored to this specific subset.
"What makes this trial so significant is that it may eventually provide answers to patient advocacy group demands for more treatment options, particularly those with less toxicity," said Eugene Ahn, MD, Medical Director of Clinical Research in Integrative Medical Oncology and Medical Oncologist at CTCA® at Midwestern. "The study utilizes the best in hormonal and HER2- targeted treatment and offers it for a longer period of time. We already know that similar regimens using less efficacious drugs for only three months can induce complete remission in roughly 20 percent of patients with triple positive breast cancer. Through this trial, we hope to observe a higher pathological complete remission rate if we use a) better combinations of drug therapies for b) a longer duration of time."
There are anticipated to be up to 32 study participants enrolled in the single-arm (non-randomized; every patient receives treatment) NEOADAPT study. The first study participant received treatment earlier this month. The goal of the trial is to determine if this chemotherapy-free approach can offer a complete pathological response (disappearance of all cancer) in at least 40 percent of study participants. A study participant may be enrolled in the trial for up to one year, or until surgery.
CTCA physicians are committed to bringing the latest technologies and advanced treatment options to their patients as quickly as possible, including promising clinical research opportunities. For more information or to enroll in the NEOADAPT clinical trial or other CTCA trials currently available, visit http://www.cancercenter.com/clinical-trials/, email MidwesternTrials@ctca-hope.com or call 888-841-9129.
- Carey, LA, Dees, EC, et al. The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes. AACR Clinical Cancer Research 2007 13(8): 2329-2334.
- Whitworth, PW, Beitsch, PD, et al. Determining whether functional subtyping with BluePrint 80-gene profile could potentially identify two distinct triple positive subtypes with and without trastuzumab/chemosensitivity. Journal of Clinical Oncology (Meeting Abstracts) 2015 33(15_supplement): 596.
About Cancer Treatment Centers of America®
Cancer Treatment Centers of America® (CTCA), headquartered in Boca Raton, Fla., is a national network of five hospitals that serves adult patients who are fighting cancer. CTCA® offers an integrative approach to care that combines advancements in genomic testing and precision cancer treatment, surgery, radiation, immunotherapy and chemotherapy, with evidence-based complementary therapies that support patients physically and emotionally, enhancing their quality of life while managing side effects both during and after treatment. CTCA serves patients from around the world at its hospitals in Atlanta, Suburban Chicago, Philadelphia, Phoenix and Tulsa. Consistently rated among U.S. hospitals that deliver the highest quality of care and patient experience, CTCA provides patients and their families with comprehensive information about their treatment options and encourages their active participation in treatment decisions. For more information, visit cancercenter.com, Facebook.com/cancercenter and Twitter.com/cancercenter.
About Cancer Treatment Centers of America® at Midwestern Regional Medical Center
Cancer Treatment Centers of America® (CTCA) at Midwestern Regional Medical Center (Midwestern) is a landmark in cancer care that uses advanced technology and precision medicine to offer treatment for adult patients battling cancer. The 72-bed hospital combines innovative conventional medical treatments with evidence-based integrative oncology services to deliver whole-person care. CTCA® at Midwestern is a Magnet Recognized® hospital, ranking among the top centers in the nation for nursing excellence. The hospital is accredited by the Foundation for the Accreditation of Cellular Therapy (FACT) at the University of Nebraska Medical Center for demonstrating compliance with the FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing and Administration. CTCA at Midwestern also holds high honors as a Certified Quality Breast Center of Excellence™, recognized by the National Quality Measures for Breast Centers Program™ (NQMBC®). For more information, visit www.cancercenter.com/midwestern.